<SEC-DOCUMENT>0001641172-25-014002.txt : 20250606
<SEC-HEADER>0001641172-25-014002.hdr.sgml : 20250606
<ACCEPTANCE-DATETIME>20250606151325
ACCESSION NUMBER:		0001641172-25-014002
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250606
DATE AS OF CHANGE:		20250606

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FibroBiologics, Inc.
		CENTRAL INDEX KEY:			0001958777
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				863329066
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-94820
		FILM NUMBER:		251030220

	BUSINESS ADDRESS:	
		STREET 1:		455 E. MEDICAL CENTER BLVD
		STREET 2:		SUITE 300
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77598
		BUSINESS PHONE:		281-671-5150

	MAIL ADDRESS:	
		STREET 1:		455 E. MEDICAL CENTER BLVD SUITE 300
		STREET 2:		SUITE 300
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77598

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FibroBiologics Inc.
		DATE OF NAME CHANGE:	20221216

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Newlin Michael F.
		CENTRAL INDEX KEY:			0002067695
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	MAIL ADDRESS:	
		STREET 1:		1414 HORSESHOE DR.
		CITY:			SUGAR LAND
		STATE:			TX
		ZIP:			77478
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Newlin Michael F. -->
          <cik>0002067695</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Common Stock, $0.00001 par value</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>08/09/2024</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001958777</issuerCik>
        <issuerName>FibroBiologics, Inc.</issuerName>
        <issuerCusip>31573L105</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>455 E. MEDICAL CENTER BLVD</com:street1>
          <com:street2>SUITE 300</com:street2>
          <com:city>HOUSTON</com:city>
          <com:stateOrCountry>TX</com:stateOrCountry>
          <com:zipCode>77598</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Mike Newlin</reportingPersonName>
      <citizenshipOrOrganization>TX</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>2134853.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>2134853.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2134853.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>5.579</classPercent>
      <typeOfReportingPerson>CO</typeOfReportingPerson>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
      <comments>Beneficial ownership percentage based on 38,262,586 shares of the Issuer's common stock, $0.00001 par value per share, issued and outstanding as of May 13, 2025 as disclosed in that certain Quarterly Report on Form 10-Q filed by the Issuer with the U.S. Securities and Exchange Commission on May 14, 2025.  Shares of common stock as disclosed herein are held in name of Golden Knight Incorporated, L.P. of which Mike Newlin is the 100% beneficial owner.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>FibroBiologics, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>455 E. MEDICAL CENTER BLVD, SUITE 300, HOUSTON, TX, 77598</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Mike Newlin</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>1414 Horseshoe Dr., Sugarland, Texas 77478</principalBusinessOfficeOrResidenceAddress>
        <citizenship>United States</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>2,134,853</amountBeneficiallyOwned>
        <classPercent>5.579%</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>2,134,853</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>0</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>2,134,853</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>0</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>Mike Newlin</reportingPersonName>
      <signatureDetails>
        <signature>/s/Mike Newlin</signature>
        <title>Investor</title>
        <date>06/05/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
